---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126244"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:11.622542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026

## Summary
- Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.
- Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.
- Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).
- Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.
- Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-126244
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126244
- JSON: https://secwatch.observer/filing/0001193125-26-126244.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126244.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $66.8 million, net income $8.6 million, EPS $0.15.
  - Period: the year ended December 31, 2025
  - Revenue: $66.8 million
  - Net income: $8.6 million
  - EPS: $0.15
  - Result: reported results
  source text: fourth quarter of 2025 was primarily due to an increase in collaboration revenue from our agreements with GSK and Pfizer. Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million for the year ended December 31, 2024. The revenue increase for the year was primarily due to the aforementioned collaboration revenue related to our
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm
- Earnings Releases
  Spero Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $41.3 million, net income $31.5 million, EPS $0.53.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Revenue: $41.3 million
  - Net income: $31.5 million
  - EPS: $0.53
  - Result: reported results
  source text: diluted net gain per share of common stock of $0.15 and a diluted net loss per share of common stock of $(1.27), respectively. • Total revenue for the fourth quarter of 2025 was $41.3 million, compared to total revenue of $15.0 million for the fourth quarter of 2024. The revenue increase for the fourth quarter of 2025 was primarily due to an increase in collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.